New drug aims to cut opioid use after joint replacement surgery
NCT ID NCT07687966
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This study tests whether a new drug called CBP-0276 can help people who have had hip or knee replacement surgery use fewer opioid painkillers. Participants take either CBP-0276 or a placebo alongside standard oxycodone for 28 days after surgery. The goal is to see if CBP-0276 reduces the number of oxycodone tablets needed to control pain, potentially lowering the risk of opioid dependence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CBP-0276
- What this could lead to
- If it works, this could point toward a way to manage post-surgery pain with fewer opioids, reducing the risk of addiction and side effects.
- What could go wrong
- This is an early-stage (Phase 2) proof-of-concept study with only 80 participants, so results may not apply broadly. The drug may not reduce opioid use more than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIP OR KNEE REPLACEMENT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Innovacion y Desarrollo de Estrategias en Salud
RECRUITINGMexico City, 14340, Mexico
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••